Vol. 3 (09) pp. 108-111

HAS DENOSUMAB PLACE IN TREATMENT OF OTOSCLEROSIS?

,
  • E NT, MSc Metabolic diseases of bones, National and Kapodistrian University of Athens, Greece.
423 Downloads 263 Views
Download Full Paper (PDF)

Abstract

Background and aim: Otosclerosis is an inflammatory disease that causes bone resorption and deposition in auditory structures, leading to conductive and/or sensorineural progressive deafness. The aim of the study was to evaluate the thesis of denosumab, a human monoclonal antibody against receptor activator of nuclear factor kappaB ligand, in treatment of otosclerosis. Methods: A review of published papers related to the mechanism of action of denosumab. Results: Denosumab increased bone affinity and demonstrated effectiveness in the treatment of osteoporosis and other metabolic bone diseases. Conclusion: Denosumab, an essential mediator of osteoclastic bone resorption, is a promising therapeutic agent for the management of otosclerosis.

Keywords

Article Analytics

How to Cite This Article

Aikaterini Drylli, MD. (2015); HAS DENOSUMAB PLACE IN TREATMENT OF OTOSCLEROSIS?, Int. J. of Adv. Res., 3 (09), 108-111, ISSN 2320-5407.

Corresponding Author

AIKATERINI DRYLLI

Creative Commons Attribution 4.0 This work is licensed under a Creative Commons Attribution 4.0 International License.